Showing 1 - 8 results of 8 for search ', HOLIDA', query time: 0.04s Refine Results
  1. 1
    THE BASIC ASPECTS OF APPLICATION OF INFORMATIONCOMMUNICATION TECHNOLOGIES IN A SMALL-SCALE BUSINESS AND PRIVATE BUSINESS IN REPUBLIC UZBEKISTAN

    THE BASIC ASPECTS OF APPLICATION OF INFORMATIONCOMMUNICATION TECHNOLOGIES IN A SMALL-SCALE BUSINESS AND PRIVATE BUSINESS IN REPUBLIC UZBEKISTAN by Holida N. Ruzmetova

    Published 2016-08-01
    Get full text
    Article
  2. 2
    Analisis pengaruh faktor internal perusahaan terhadap return saham di Bursa Efek Indonesia :: Studi kasus pada PT. Pembangunan Jaya Ancol, Tbk

    Analisis pengaruh faktor internal perusahaan terhadap return saham di Bursa Efek Indonesia :: Studi kasus pada PT. Pembangunan Jaya Ancol, Tbk by , HOLIDA, , Drs. Ahmad Jamli, M.A

    Published 2009
    Thesis
  3. 3
    PENERAPAN ANIMASI INTERAKTIF DALAM PENGENALAN AKSARA SUNDA

    PENERAPAN ANIMASI INTERAKTIF DALAM PENGENALAN AKSARA SUNDA by Siti Maria Holida, Tuti Alawiyah, Herlan Sutisna

    Published 2016-03-01
    Get full text
    Article
  4. 4
    Improved Cattle Disease Diagnosis Based on Fuzzy Logic Algorithms

    Improved Cattle Disease Diagnosis Based on Fuzzy Logic Algorithms by Dilmurod Turimov Mustapoevich, Dilnoz Muhamediyeva Tulkunovna, Lola Safarova Ulmasovna, Holida Primova, Wooseong Kim

    Published 2023-02-01
    Get full text
    Article
  5. 5
    P033: Cardiac manifestations of Fabry disease: Insights from a clinic population through cardiac magnetic resonance imaging

    P033: Cardiac manifestations of Fabry disease: Insights from a clinic population through cardiac magnetic resonance imaging by Darby Manternach, Lindsey Reinhardt, Lauren VanOpdorp, Myrl Holida, Ravi Ashwath, Mahi Ashwath, John Bernat

    Published 2024-01-01
    Get full text
    Article
  6. 6
    P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51

    P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51 by John Bernat, Myrl Holida, Nicola Longo, Ozlem Goker-Alpan, Eric Wallace, Patrick Deegan, Camilla Tondel, Francois Eyskens, Ulla Feldt-Rasmussen, Derralynn Hughes, Antonio Pisani, Ales Linhart, Rossana Rocco, Einat Almon, Sari Alon, Raul Chertkoff, David Warnock, Stephen Waldek, William Wilcox

    Published 2023-01-01
    Get full text
    Article
  7. 7
    Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

    Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. by David G Warnock, Daniel G Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mark Thomas, Francois Eyskens, Suma Shankar, Mathews Adera, Sheela Sitaraman, Richie Khanna, John J Flanagan, Brandon A Wustman, Jay Barth, Carrolee Barlow, Kenneth J Valenzano, David J Lockhart, Pol Boudes, Franklin K Johnson

    Published 2015-01-01
    Get full text
    Article
  8. 8
    P005: Head-to-head trial of pegunigalsidase alfa vs agalsidase beta in Fabry disease: Phase 3 randomized, double-blind, BALANCE Study 2-year results

    P005: Head-to-head trial of pegunigalsidase alfa vs agalsidase beta in Fabry disease: Phase 3 randomized, double-blind, BALANCE Study 2-year results by John Bernat, Eric Wallace, Ozlem Goker-Alpan, William Wilcox, Myrl Holida, Nicola Longo, Derralynn Hughes, Pilar Giraldo, Maria Molnar, Damara Ortiz, Robert Hopkin, Camilla Tondel, Ales Linhart, Patrick Deegan, Ana Jovanovic, Michael Muriello, Bruce Barshop, Virginia Kimonis, Bojan Vujkovac, Albina Nowak, Tarekegn Hiwot, Antonio Pisani, Dominique Germain, Ilkka Kantola, Jasmine Knoll, Ankit Mehta, Stephen Waldek, Einat Almon, Sari Alon, Raul Chertkoff, Rossana Rocco, David Warnock

    Published 2023-01-01
    Get full text
    Article

Search Tools: